Regeneron Pharmaceuticals received Priority Review by the U.S. FDA for a new Biologics License Application (BLA) for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus infection. The target action date for the FDA decision is October 25, 2020. The REGN-EB3 BLA is supported by data from the randomized, controlled PALM clinical trial demonstrating superior efficacy compared to the control arm across multiple measures, including reduced mortality and fewer days until...